Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies

Haematologica

Volumn 100, Issue 8, 2015, Pages 997-1004

  Lehmberg, Kai ^a   Nichols, Kim E ^b   Henter, Jan Inge ^c   Girschikofsky, Michael ^d   Greenwood, Tatiana ^c   Jordan, Michael ^e   Kumar, Ashish ^e   Minkov, Milen ^f   Rosée, Paul La ^g   Weitzman, Sheila ^h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d ELISABETHINEN HOSPITAL   (Austria)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f ST ANNA CHILDREN S HOSPITAL   (Austria)

^g JENA UNIVERSITY HOSPITAL   (Germany)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMINOTRANSFERASE; ANTIINFECTIVE AGENT; ASPARAGINASE; BILIRUBIN; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; D DIMER; DOXORUBICIN; ETOPOSIDE; FERRITIN; FLUDARABINE; GLUCOCORTICOID; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY; VINBLASTINE; VINCRISTINE;

AGE; ARTICLE; BONE MARROW BIOPSY; CELL THERAPY; CEREBROSPINAL FLUID ANALYSIS; CHEMOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; EPSTEIN BARR VIRUS INFECTION; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC SYNDROME; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LARGE CELL LYMPHOMA; MEDICAL LITERATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PUBLICATION; SURVIVAL; T CELL LYMPHOMA; X CHROMOSOME LINKED DISORDER; X LINKED LYMPHOPROLIFERATIVE SYNDROME; COMPLICATION; DISEASE MANAGEMENT; NEOPLASMS; PRACTICE GUIDELINE;

DISEASE MANAGEMENT; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; NEOPLASMS;

EID: 84938600240     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.123562     Document Type: Article

References (73)

1. Al-Hashmi I, Decoteau J, Gruss HJ, et al. Establishment of a cytokine-producing anaplastic large-cell lymphoma cell line containing the t(2;5) translocation: Potential role of cytokines in clinical manifestations. Leuk Lymphoma. 2001;40(5-6):599-611
2. Siebert S, Amos N, Williams BD, Lawson TM. Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome. Semin Arthritis Rheum. 2007;37(1):63-67
3. Perez-Encinas M, Villamayor M, Campos A, Gonzalez S, Bello JL. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. Haematologica1998;83(8):752-754
4. Janik JE, Morris JC, Pittaluga S, et al. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood. 2004;104(10):3355-3357
5. Menard F, Besson C, Rince P, et al. Hodgkin lymphoma-associated hemophagocytic syndrome: A disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis. 2008;47(4):531-534
6. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syn-drome: A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer. 1979;44(3):993-1002
7. Celkan T, Berrak S, Kazanci E, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: A multicenter study from Turkey. Turk J Pediatr. 2009;51(3):207-213
8. Trebo MM, Attarbaschi A, Mann G, Minkov M, Kornmuller R, Gadner H. Histiocytosis following T-acute lymphoblastic leukemia: A BFM study. Leuk Lymphoma. 2005;46(12):1735-1741
9. Delavigne K, Berard E, Bertoli S, et al. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy. Haematologica. 2014;99(3):474-480
10. Kelly C, Salvi S, McClain K, Hayani A. Hemophagocytic lymphohistiocytosis associated with precursor B acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(4):658-660
11. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516
12. Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58-65
13. Riviere S, Galicier L, Coppo P, et al. Reactive hemophagocytic syndrome in adults: A multicenter retrospective analysis of 162 patients. Am J Med. 2014; 127(11):1118-25
14. Li J, Wang Q, Zheng W, et al. Hemophagocytic lymphohistiocytosis: Clinical analysis of 103 adult patients. Medicine (Baltimore). 2014;93(2):100-105
15. Yu JT, Wang CY, Yang Y, et al. Lymphomaassociated hemophagocytic lymphohistiocytosis: Experience in adults from a single institution. Ann Hematol. 2013; 92(11):1529-1536
16. Han AR, Lee HR, Park BB, et al. Lymphomaassociated hemophagocytic syndrome: Clinical features and treatment outcome. Ann Hematol. 2007;86(7):493-498
17. Veerakul G, Sanpakit K, Tanphaichitr VS, Mahasandana C, Jirarattanasopa N. Secondary hemophagocytic lymphohistiocytosis in children: An analysis of etiology and outcome. J Med Assoc Thai. 2002;85 Suppl 2:S530-541
18. Lehmberg K, Sprekels B, Nichols KE, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;May4[Epub ahead of print]
19. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: A systematic analysis of 156 patients reported in the literature. Cancer. 2004;101(6):1404-1413
20. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838-845
21. Ferreri AJ, Dognini GP, Campo E, et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica. 2007;92(4):486-492
22. Hagihara M, Inoue M, Hua J, Iwaki Y. Lymphocyte-depleted Hodgkin lymphoma complicating hemophagocytic lymphohistiocytosis as an initial manifestation: A case report and review of the literature. Intern Med. 2012;51(21):3067-3072
23. Cho EY, Kim KH, Kim WS, Yoo KH, Koo HH, Ko YH. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: Incidence of disease entities by age groups. J Korean Med Sci. 2008;23(2):185-192
24. Chang YH, Lu PJ, Lu MY, Wang JS, Tung CL, Shaw CF. Sequential transplants for respective relapse of Hodgkin disease and hemophagocytic lymphohistiocytosis: A treatment dilemma. J Pediatr Hematol Oncol. 2009;31(10):778-781
25. Shimazaki C, Inaba T, Nakagawa M. B-cell lymphoma-associated hemophagocytic syndrome. Leuk Lymphoma. 2000;38(1-2):121-130
26. Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: Clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol. 2000;111(3):826-834
27. Hong M, Ko YH, Yoo KH, et al. EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood. Korean J Pathol. 2013;47(2):137-147
28. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: Prospective analysis of 108 cases. Blood. 2012;119(3):673-686
29. Stebbing J, Ngan S, Ibrahim H, et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease. Clin Exp Immunol. 2008;154(3):399-405
30. Aronson IK, Worobec SM. Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: An overview. Dermatol Ther. 2010;23(4):389-402
31. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med. 1990;322(20):1425-1429
32. Imashuku S. Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):121-123
33. Lackner H, Urban C, Sovinz P, Benesch M, Moser A, Schwinger W. Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children. Haematologica. 2008;93(2):291-294
34. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-5157
35. Machaczka M, Vaktnas J, Klimkowska M, Hagglund H. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: A retrospective population-based analysis from a single center. Leuk Lymphoma. 2011;52(4):613-619
36. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2): 124-131
37. Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;51(3):402-404
38. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052
39. Lehmberg K, McClain KL, Janka GE, Allen CE. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2014;61(11):2101-2103
40. Takahashi N, Chubachi A, Miura I, Nakamura S, Miura AB. [Lymphoma-associated hemophagocytic syndrome in Japan]. Rinsho Ketsueki. 1999;40(7):542-549
41. Fardet L, Galicier L, Lambotte O, et al. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620
42. Lehmberg K, Ehl S. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol. 2012;160(3):275-287
43. Fardet L, Lambotte O, Meynard JL, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: Clinical features, underlying diseases and prognosis. Aids. 2010;24(9):1299-1306
44. Suga K, Kawakami Y, Hiyama A, et al. F-18 FDG PET/CT findings in a case of T-cell lymphoma-associated hemophagocytic syndrome with liver involvement. Clin Nucl Med. 2010;35(2):116-120
45. Horne A, Trottestam H, Arico M, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol. 2008;140(3):327-335
46. Deiva K, Mahlaoui N, Beaudonnet F, et al. CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology. 2012;78(15):1150-1156
47. Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-5798
48. Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 2012;119(12):2754-2763
49. Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: A multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53-62
50. Marsh RA, Bleesing JJ, Filipovich AH. Flow cytometric measurement of SLAM-associated protein and X-linked inhibitor of apoptosis. Methods Mol Biol. 2013;979:189-197
51. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192(5):755-760
52. Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proc Natl Acad Sci USA. 2009; 106(24):9809-9814
53. Clementi R, Locatelli F, Dupre L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. 2005;105(11):4424-4428
54. Zur Stadt U, Beutel K, Weber B, Kabisch H, Schneppenheim R, Janka G. A91V is a polymorphism in the perforin gene not causative of an FHLH phenotype. Blood. 2004;104(6):1909; author reply 1910
55. Mehta PA, Davies SM, Kumar A, et al. Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group. Leukemia. 2006;20(9):1539-1541
56. Santoro A, Cannella S, Trizzino A, Lo Nigro L, Corsello G, Arico M. A single amino acid change A91V in perforin: A novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica. 2005;90(5):697-698
57. Trapani JA, Thia KY, Andrews M, et al. Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology. 2013;2(4):e24185
58. Machaczka M, Klimkowska M, Chiang SC, et al. Development of classical Hodgkin's lymphoma in an adult with biallelic STXBP2 mutations. Haematologica. 2013;98(5):760-764
59. Lorenzi L, Tabellini G, Vermi W, et al. Occurrence of nodular lymphocyte-predominant hodgkin lymphoma in hermanskypudlak type 2 syndrome is associated to natural killer and natural killer T cell defects. PLoS One. 2013;8(11):e80131
60. Nagai K, Ochi F, Terui K, et al. Clinical characteristics and outcomes of chediak-Higashi syndrome: A nationwide survey of Japan. Pediatr Blood Cancer. 2013;60(10):1582-1586
61. Pagel J, Beutel K, Lehmberg K, et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood. 2012;119(25):6016-6024
62. Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622-628
63. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109
64. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289-298
65. Takahashi N, Chubachi A, Kume M, et al. A clinical analysis of 52 adult patients with hemophagocytic syndrome: The prognostic significance of the underlying diseases. Int J Hematol. 2001;74(2):209-213
66. Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: Impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015; 168(1):63-8
67. Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192 (1):84-91
68. Mizutani S, Kuroda J, Shimura Y, et al. Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematol. 2011;126(1):8-12
69. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-28
70. Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162 (3):376-382
71. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89 (4):484-492
72. Tong H, Ren Y, Liu H, et al. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: Comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma. 2008;49(1):81-87
73. Lackner H, Seidel MG, Strenger V, et al. Hemophagocytic syndrome in children with acute monoblastic leukemia-another cause of fever of unknown origin. Support Care Cancer. 2013;21(12):3519-3523.